Kamada Ltd.

Tel Aviv Stock Exchange:KMDA.TA

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

🧬 Biotechnology

💊 Drugstores & Retail Pharmacies

💊 Pharmaceuticals

💉 Vaccines

Location

Israel

Market Cap

USD 452.65 M

Share Price

USD 7.87

Avg Daily Volume

83,650

Change (1 day)

1.02%

Change (1 year)

58.53%

Change (YTD)

32.18%

Kamada Ltd. Total Assets for the year ending December 31, 2024: USD 372.25 M

Kamada Ltd. Total Assets is USD 372.25 M for the year ending December 31, 2024, a 4.89% change year over year. Total assets are the total value of all assets owned by a company, representing its resources.

Kamada Ltd. Total Assets for the year ending December 31, 2023 was USD 354.91 M, a 10.09% change year over year.
Kamada Ltd. Total Assets for the year ending December 31, 2022 was USD 322.38 M, a 1.16% change year over year.
Kamada Ltd. Total Assets for the year ending December 31, 2021 was USD 318.67 M, a 51.27% change year over year.
Kamada Ltd. Total Assets for the year ending December 31, 2020 was USD 210.66 M, a 21.21% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Total Assets	Accounts Payable	Short-Term Debt	Long-Term Debt

Tel Aviv Stock Exchange: KMDA.TA

Kamada Ltd.

CEO	Mr. Amir London
IPO Date	Aug. 31, 2005
Location	Israel
Headquarters	2 Holzman Street
Employees	420
Sector	🏥 Health Care
Industries Clinical Trials 🧬 Biotechnology 💊 Drugstores & Retail Pharmacies 💊 Pharmaceuticals 💉 Vaccines

Description

Kamada Ltd. provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers KAMRAB/KEDRAB for prophylaxis of rabies disease; CYTOGAM for prophylaxis of cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplant; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; VARIZIG for post exposure prophylaxis of varicella; and GLASSIA for intravenous AATD. It also provides KamRho (D) IM for prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus. In addition, the company distributes BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN for Allergic rhinitis and Urticaria; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for cytomegalovirus virus; RUCONEST for angioedema attacks; heparin sodium injection for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. Further, it offers IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis ; and ELIGARD for prostate cancer. The company markets its products through strategic partners in the United States, as well as through distributors internationally. Kamada Ltd. has strategic partnerships with Takeda Pharmaceuticals Company Limited; PARI GmbH; and Kedrion Biopharma. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.